A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Aurora, Houston, Minneapolis, Modesto, Richmond, and South Euclid, United StatesSee the 6 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 96 people, planned
- Started
- 7 Oct 2026
- Expected to end
- 7 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- mRNA-1010
- Fluarix Trivalent
- Record updated
- 5 November 2026
Who can take part
- Age
- 9 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- 9 to <18 years of age inclusive, at the time of signing the informed consent/assent
- In the Investigator's opinion, the participants/participant's parent(s)/legally authorized representative (LAR(s)) demonstrate adequate understanding of the study requirements and are willing and physically able to comply with protocol mandated follow-up, including all procedures
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration
Who cannot take part
- Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the window specified for Screening
- Any prior systemic immunosuppressants, immunomodulators (for example, methotrexate, cyclosporine), or long-acting biological therapies that may affect immune responses (for example, dupilumab, omalizumab). Short courses (<7 days) of oral corticosteroids are allowed if completed at least 3 months prior to Day 1. Inhaled, nasal, topical steroids, and subcutaneous injected allergy immunotherapy (allergy shots) are allowed
- Received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive them during the study
- Received any nonstudy vaccine authorized or approved by local health agency within 14 days (28 days for live vaccines and mRNA vaccines) prior to Day 1 (inclusive) or plans to receive any nonstudy vaccine within 28 days post study vaccine administration
- Donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study vaccine administration; Note: Other protocol-defined inclusion and exclusion criteria may apply
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic; influenza vaccine; or components of influenza vaccine, including egg protein
- History of a diagnosis or condition not specifically listed as exclusionary that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Seasonal influenza
This trial is currently available in United States.
- Paradigm Clinical Research Centers, LLCAurora, United StatesContact: Moderna WeCare TeamTaking people
- West Houston Clinical Research ServiceHouston, United StatesContact: Moderna WeCare TeamTaking people
- Clinical Research Institute, Inc.Minneapolis, United StatesContact: Moderna WeCare TeamTaking people
- Paradigm Clinical Research Centers, LLCModesto, United StatesContact: Moderna WeCare TeamTaking people
- Clinical Research Partners, LLCRichmond, United StatesContact: Moderna WeCare TeamTaking people
- Senders PediatricsSouth Euclid, United StatesContact: Moderna WeCare TeamTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
The 3 groups in the trial
- mRNA-1010 Low DoseTreatment being tested
Participants will receive a single low dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
Treatment: mRNA-1010
- mRNA-1010 Full DoseTreatment being tested
Participants will receive a single full dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
Treatment: mRNA-1010
- Fluarix TrivalentExisting treatment, for comparison
Participants will receive a single dose of Fluarix Trivalent by IM injection on Day 1.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)
- Criteria questions
- Built from NCT07870330, who can take part
- Record updated
- 5 November 2026